Trifluridine/tipiracil is marketed as LONSURF, an oral fixed-dose anticancer combination for previously treated metastatic colorectal cancer and metastatic gastric/gastroesophageal junction adenocarcinoma. The formulation combines a nucleoside metabolic inhibitor (trifluridine) with a thymidine phosphorylase inhibitor (tipiracil). U.S. initial approval was in 2015.
Alphamab Oncology dosed the first patient in its Phase III trial of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, for HER2-positive advanced colorectal cancer on February 14, 2026.
Alphamab Oncology has dosed the first patient in a Phase III study of JSKN003, a biparatopic HER2-targeting ADC, for HER2-positive advanced colorectal cancer. The drug demonstrated a 68.8% response rate in earlier trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07280377 |
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT05468892 |
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial |
COMPLETED | PHASE2 |
